Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications

Recruiting now · Not applicable

Conditions studied: Liver Cirrhosis

In brief

Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.

Key facts

Study ID

NCT07201649

Run by

Centre Hospitalier Universitaire de Nice

People needed

95

Starts

2025-11-24

Expected to finish

2029-11-24

Last updated by the study team

2025-12-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• everyone requiring liver transplantation for the treatment of a chronic liver disease

You may not qualify if…

• MELD score >25, viral replication

Where it is running

• CHU de Nice — Nice, Alpes-maritimes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.